Budd-Chiari Syndrome in China: Balloon Angioplasty Alone or Combined With Stent Placement?

Overview

Budd-Chiari syndrome (BCS) is defined as the hepatic outflow obstruction from the small hepatic veins to the confluence between inferior vena cava and right atrium, which often leads to the life-threatening complications, such as liver failure and portal hypertension-related complications. At present, a stepwise treatment strategy is employed, including anticoagulation, thrombolysis, percutaneous recanalization (i.e., percutaneous transluminal angioplasty [PTA] alone or in combination with stent placement), transjugular intrahepatic portosystemic shunt, and liver transplantation. In West, only less than 20% of BCS patients underwent percutaneous recanalization; by contrast, percutaneous recanalization is the most common treatment modality used in China. Recently, an 11-year retrospective case series of 177 Chinese patients with primary BCS has shown a higher rate of re-occlusion in the PTA alone group than in the PTA combined with stent placement group (31% versus 7.7%, p<0.001). In addition, re-occlusion was regarded as the independent predictor of mortality. Accordingly, we hypothesized that PTA alone might have a worse survival than PTA combined with stent placement in Chinese patients with primary BCS.

Full Title of Study: “Balloon Angioplasty Alone Versus in Combination With Stent Placement for the Treatment of Budd-Chiari Syndrome in China: An Randomized Controlled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Care Provider)
  • Study Primary Completion Date: September 2017

Interventions

  • Device: Stent
  • Device: Balloon

Arms, Groups and Cohorts

  • Active Comparator: PTA in combination with stent-placement
    • In this group, the patients will undergo percutaneous balloon angioplasty with or without stent-placement angioplasty in combination with stent-placement.
  • Active Comparator: PTA alone
    • In this group, the patients will undergo percutaneous balloon angioplasty alone. The patients will transfer to the stent placement in the following cases: 1) reocclusion with thrombosis; and 2) at least 2 reocclusion events.

Clinical Trial Outcome Measures

Primary Measures

  • The incidence of reocclusion between PTA alone and in combination with stent-placement groups
    • Time Frame: 2 years

Secondary Measures

  • The survival between PTA alone and in combination with stent placement groups
    • Time Frame: 2 years
  • The incidence of procedure-related complications between PTA alone and in combination with stent placement groups
    • Time Frame: 2 years
  • The length of hospitalization between PTA alone and in combination with stent placement groups
    • Time Frame: 2 years
  • The symptom recurrence rate between PTA alone and in combination with stent placement groups
    • Time Frame: 2 years

Participating in This Clinical Trial

Inclusion Criteria

1. Informed consent. 2. Age 18-75 years old. 3. Budd-Chiari syndrome 4. Child-Pugh score <13 points. 5. Eligible for percutaneous recanalization. Exclusion Criteria:

1. Pregnancy or lactation. 2. Malignancy. 3. HIV infection. 4. Severe cardiac or lung diseases. 5. Severe renal dysfunction (serum> 265.2 umol/l). 6. Uncontrolled systemic infection. 7. Allergic to contrast agents. 8. Poor compliance. 9. A prior history of percutaneous recanalization. 10. Ineligible for percutaneous recanalization. 11. Liver cirrhosis with severe portal hypertension-related complications. 12. Acute liver failure. 13. Progressive deterioration of liver function.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Air Force Military Medical University, China
  • Provider of Information About this Clinical Study
    • Principal Investigator: Guohong Han, Professor – Air Force Military Medical University, China
  • Overall Official(s)
    • Guohong Han, MD, Principal Investigator, Xijing Hospital of Digestive Diseases, Fourth Military Medical University

References

Han G, Qi X, Zhang W, He C, Yin Z, Wang J, Xia J, Xu K, Guo W, Niu J, Wu K, Fan D. Percutaneous recanalization for Budd-Chiari syndrome: an 11-year retrospective study on patency and survival in 177 Chinese patients from a single center. Radiology. 2013 Feb;266(2):657-67. doi: 10.1148/radiol.12120856. Epub 2012 Nov 9.

Qi X, Han G. Images in clinical medicine. Abdominal-wall varices in the Budd-Chiari syndrome. N Engl J Med. 2014 May 8;370(19):1829. doi: 10.1056/NEJMicm1308567. No abstract available.

Qi X, Wu F, Ren W, He C, Yin Z, Niu J, Bai M, Yang Z, Wu K, Fan D, Han G. Thrombotic risk factors in Chinese Budd-Chiari syndrome patients. An observational study with a systematic review of the literature. Thromb Haemost. 2013 May;109(5):878-84. doi: 10.1160/TH12-10-0784. Epub 2013 Feb 28.

Qi X, Wu F, Fan D, Han G. Prevalence of thrombotic risk factors in Chinese Budd-Chiari syndrome patients: results of a prospective validation study. Eur J Gastroenterol Hepatol. 2014 May;26(5):576-7. doi: 10.1097/MEG.0000000000000056. No abstract available.

Qi X, Guo W, He C, Zhang W, Wu F, Yin Z, Bai M, Niu J, Yang Z, Fan D, Han G. Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome: techniques, indications and results on 51 Chinese patients from a single centre. Liver Int. 2014 Sep;34(8):1164-75. doi: 10.1111/liv.12355. Epub 2013 Nov 20.

Qi X, Han G, Guo W, Yin Z, Fan D. Education and Imaging. Hepatobiliary and pancreatic: Budd-Chiari syndrome with infra-hepatic obstruction of inferior vena cava. J Gastroenterol Hepatol. 2013 Jun;28(6):905. doi: 10.1111/jgh.12228. No abstract available.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.